<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795340</url>
  </required_header>
  <id_info>
    <org_study_id>BR29</org_study_id>
    <secondary_id>CAN-NCIC-BR29</secondary_id>
    <secondary_id>CDR0000618671</secondary_id>
    <nct_id>NCT00795340</nct_id>
  </id_info>
  <brief_title>Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Double Blind Randomized Trial of Cediranib Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Cediranib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work
      in different ways to stop the growth of tumor cells, either by killing the cells or by
      stopping them from dividing. It is not yet known whether cediranib is more effective than a
      placebo when given together with paclitaxel and carboplatin in treating patients with
      non-small cell lung cancer.

      PURPOSE: This randomized phase III trial is studying how well cediranib works when given
      together with paclitaxel and carboplatin in treating patients with stage IIIB or stage IV
      non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To compare overall survival of patients with stage IIIB-IV non-small cell lung cancer
           treated with cediranib vs placebo administered in combination with paclitaxel and
           carboplatin.

      Secondary

        -  To compare the progression-free survival of patients treated with these regimens.

        -  To compare the objective response rates in patients treated with these regimens.

        -  To estimate time to response and response duration in patients treated with these
           regimens.

        -  To evaluate the nature, severity, and frequency of toxicities, including hemorrhage and
           hemoptysis, in patients treated with these regimens.

        -  To compare the pharmacokinetics of paclitaxel between the two arms in a subset of
           enrolled patients

        -  To compare the quality of life of patients treated with these regimens.

        -  To determine the incremental cost effectiveness and cost utility ratios for these
           regimens.

        -  To correlate the expression of tissue markers (at diagnosis) with outcomes and response
           in an exploratory fashion OUTLINE: This is a multicenter study. Patients are stratified
           by gender, center, disease stage (IIIB vs IV), weight loss (&lt; 5% vs 5-10% vs unknown),
           and prior adjuvant chemotherapy (yes vs no). Patients are randomized to 1 of 2 treatment
           arms.

        -  Arm I: Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3
           hours and carboplatin IV over 30 minutes on day 1.

        -  Arm II: Patients receive oral placebo once daily on days 1-21 and paclitaxel and
           carboplatin as in arm I.

      Treatment in both arms repeats every 21 days for 4 to 6 courses in the absence of disease
      progression or unacceptable toxicity.

      Quality of life is assessed at baseline, on day 1 of each course, and periodically
      thereafter.

      After completion of study therapy, patients are followed every 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>at every 3 months visit throughout trial, a median of 13.1 months.</time_frame>
    <description>Medians of survival time, and their confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>at every 3 months visit throughout trial, a median of 12 months</time_frame>
    <description>Medians of PFS and their confidence intervals by arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Tumor Response as Assessed by RECIST Criteria v1.1.</measure>
    <time_frame>Every 6 weeks at the end of every 2 cycles during protocol treatment and every 12 weeks after protocol treatment until progression.</time_frame>
    <description>Every 6 weeks at the end of every 2 cycles during protocol treatment and every 12 weeks after protocol treatment until progression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I Cediranib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I Cediranib</arm_group_label>
    <arm_group_label>Arm II Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cediranib maleate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I Cediranib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I Cediranib</arm_group_label>
    <arm_group_label>Arm II Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically* confirmed non-small cell carcinoma of the lung

               -  Stage IIIB or IV disease NOTE: *Diagnosis by sputum cytology alone allowed
                  provided it is confirmed by a second sputum specimen

          -  Measurable disease, defined as at least 1 measurable lesion &gt; 20 mm by x-ray,
             ultrasound, or physical exam or ≥ 10 mm (lymph nodes must be ≥ 15 mm in the short
             axis) by spiral CT scan or physical exam (in the first 260 patients randomized**)

               -  Measurable lesions that are sole sites of disease must be outside a previous
                  radiotherapy field unless disease progression has been documented NOTE:
                  **Measurable or nonmeasurable disease allowed after the first 260 patients

          -  No appreciable cavitation in central thoracic lesions

          -  No untreated brain or meningeal metastases

               -  Patients with treated and radiologic or clinical evidence of stable brain
                  metastases, with no evidence of cavitation or hemorrhage in the brain lesion, are
                  eligible provided the metastases are asymptomatic and do not require
                  corticosteroids

          -  No pleural effusion

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Absolute granulocyte count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Creatinine clearance &gt; 50 mL/min

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  ALT ≤ 2 times ULN (&lt; 5 times ULN if due to liver metastasis)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective double-method contraception (barrier method for
             men)

          -  No other malignancy within the past 5 years, except in situ cancer, basal cell or
             squamous cell skin cancer, or malignancy cured by definitive prior therapy alone
             (e.g., surgery) and continuously disease-free for at least 5 years

          -  Mean QTc with Bazett correction ≤ 480 msec in screening ECG (at least one value must
             be ≤ 480 msec when measured automatically or manually corrected using Bazett's or
             Fridericia's correction)

          -  No history of familial long QT syndrome

          -  No untreated and/or uncontrolled cardiovascular conditions and/or symptomatic cardiac
             dysfunction including any of the following:

               -  Unstable angina

               -  Congestive heart failure

               -  Myocardial infarction within the past year

               -  Cardiac ventricular arrhythmias requiring medication

               -  History of second or third degree atrioventricular conduction defects

          -  LVEF &gt; 50% in patients with significant cardiac history, even if controlled

          -  No resting BP consistently &gt; 150 mm Hg systolic and/or &gt; 100 mm Hg diastolic

          -  No poorly controlled hypertension

          -  No history of labile hypertension or poor compliance with anti-hypertensive medication

          -  No overt bleeding (&gt; 30 mL bleeding/episode) from any site within the past 3 months

          -  No clinically relevant hemoptysis (&gt; 5 mL fresh blood) within the past 4 weeks

               -  Flecks of blood in sputum allowed

          -  No active or uncontrolled infections, or serious illnesses or medical conditions which
             would not permit the patient to be treated according to the study

          -  No prior allergic reactions to drugs containing Cremophor EL®

          -  No inflammatory bowel disease (e.g., Crohn disease or ulcerative colitis)

          -  No documented weight loss &gt; 10% within the past 3 months

               -  Patients with weight loss 5-10% or whose weight loss status is unknown are
                  eligible provided serum albumin levels are ≥ 30 g/L

          -  No peripheral neuropathy &gt; grade 1

          -  Must be fit for combined modality treatment

          -  Sufficiently fluent and willing to complete quality-of-life questionnaires

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from all prior therapy

          -  No prior chemotherapy for metastatic or recurrent disease

          -  No prior anti-angiogenic therapy (e.g., bevacizumab, cediranib, AZD6474, PTK/ZK,
             sunitinib malate, or other agents considered angiogenesis inhibitors by NCIC Clinical
             Trials Group for any indication)

               -  Prior cox-2 inhibitors in standard doses allowed

          -  At least 12 months since prior adjuvant chemotherapy for completely resected disease

               -  Combined chemotherapy/radiotherapy regimens for locally advanced stage IIIB
                  disease not allowed

          -  At least 21 days since prior radiotherapy

          -  At least 21 days since prior cetuximab or other monoclonal antibodies

          -  At least 14 days since prior EGFR inhibitor therapy for adjuvant therapy or metastatic
             disease (e.g., tyrosine kinase inhibitors, vaccines, or other agents considered by
             NCIC CTG as acting on the EGFR pathway)

          -  At least 14 days since prior major surgery

          -  At least 1 week since prior corticosteroids

          -  No other concurrent experimental drugs, anticancer treatment, or investigational
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott A. Laurie, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Ottawa Regional Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Cancer (INCA)</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>CEP20231-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Cancer Arnaldo Vieira de Carvalho</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01224-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Abbotsford Centre</name>
      <address>
        <city>Abbotsford</city>
        <state>British Columbia</state>
        <zip>V2S 0C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute - General Division</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algoma District Cancer Program</name>
      <address>
        <city>Sault Ste. Marie</city>
        <state>Ontario</state>
        <zip>P6B 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagara Health System</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2R 7C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Institute of Cardiology and</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, Stockler MR, Lee CW, Chen EX, Montenegro A, Ding K, Bradbury PA. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer. 2014 Mar;50(4):706-12. doi: 10.1016/j.ejca.2013.11.032. Epub 2013 Dec 17.</citation>
    <PMID>24360368</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <results_first_submitted>April 28, 2015</results_first_submitted>
  <results_first_submitted_qc>November 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2015</results_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cediranib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cediranib</title>
          <description>Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
carboplatin: Given IV
cediranib maleate: Given orally
paclitaxel: Given IV</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.
carboplatin: Given IV
paclitaxel: Given IV
placebo: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention to treat population</population>
      <group_list>
        <group group_id="B1">
          <title>Cediranib</title>
          <description>Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
carboplatin: Given IV
cediranib maleate: Given orally
paclitaxel: Given IV</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.
carboplatin: Given IV
paclitaxel: Given IV
placebo: Given orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
            <count group_id="B2" value="153"/>
            <count group_id="B3" value="306"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="23" upper_limit="85"/>
                    <measurement group_id="B2" value="62" lower_limit="36" upper_limit="77"/>
                    <measurement group_id="B3" value="62" lower_limit="23" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aboriginal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Medians of survival time, and their confidence intervals.</description>
        <time_frame>at every 3 months visit throughout trial, a median of 13.1 months.</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Cediranib</title>
            <description>Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
carboplatin: Given IV
cediranib maleate: Given orally
paclitaxel: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.
carboplatin: Given IV
paclitaxel: Given IV
placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Medians of survival time, and their confidence intervals.</description>
          <population>ITT</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="9.1" upper_limit="18.0"/>
                    <measurement group_id="O2" value="12.1" lower_limit="11.1" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Medians of PFS and their confidence intervals by arm</description>
        <time_frame>at every 3 months visit throughout trial, a median of 12 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Cediranib</title>
            <description>Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
carboplatin: Given IV
cediranib maleate: Given orally
paclitaxel: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.
carboplatin: Given IV
paclitaxel: Given IV
placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Medians of PFS and their confidence intervals by arm</description>
          <population>ITT</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.52" lower_limit="4.86" upper_limit="6.05"/>
                    <measurement group_id="O2" value="5.45" lower_limit="4.86" upper_limit="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Tumor Response as Assessed by RECIST Criteria v1.1.</title>
        <description>Every 6 weeks at the end of every 2 cycles during protocol treatment and every 12 weeks after protocol treatment until progression.</description>
        <time_frame>Every 6 weeks at the end of every 2 cycles during protocol treatment and every 12 weeks after protocol treatment until progression.</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Cediranib</title>
            <description>Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
carboplatin: Given IV
cediranib maleate: Given orally
paclitaxel: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.
carboplatin: Given IV
paclitaxel: Given IV
placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response as Assessed by RECIST Criteria v1.1.</title>
          <description>Every 6 weeks at the end of every 2 cycles during protocol treatment and every 12 weeks after protocol treatment until progression.</description>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="44" upper_limit="60"/>
                    <measurement group_id="O2" value="34" lower_limit="26" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from the start of treatment to time of 4 weeks after stopped the treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cediranib</title>
          <description>Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE Version 3.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Mucositis (functional/symptomatic) Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Obstruction, GI Small bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Perforation, GI Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Death Disease progression NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Chest/thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pain Liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Colitis, infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically) Blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically) Colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically) Lung</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically) Meninges</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically) Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically) Upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Anal/perianal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Bladder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Larynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Lung</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism (vascular access)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>cTnI</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness Extremity-lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Muscle weakness Whole body/generalized</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Back</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Muscle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pain Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>CNS ischemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial CN VIII</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GU Urinary NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary Lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hiccoughs</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI CTCAE Version 3.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular arrhythmia Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing (without monitoring program)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Mucositis (clinical exam) Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Mucositis (functional/symptomatic) Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Chest/thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC Lung</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC Upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Muscle weakness Extremity-lower</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Muscle weakness Whole body/generalized</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Back</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Bone</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Chest wall</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Joint</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Muscle</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Neck</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pain Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Mood alteration Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Mood alteration Depression</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary Lung</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary Nose</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hiccoughs</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Voice changes</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hand-foot</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination at phase II part of the trial, leading to small numbers of subjects analyzed, and limited follow up time.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Scott Laurie</name_or_title>
      <organization>Division of Medical Oncology, the Ottawa Hospital, Ottawa, Ontario, Canada</organization>
      <phone>1-613-737-7700</phone>
      <email>slaurie@toh.on.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

